FDA Approved: ZORYVE — Supplemental Application (Arcutis Biotherapeutics, Inc.)

View source ↗

Summary

FDA notes a supplemental application for ZORYVE (roflumilast) by Arcutis Biotherapeutics to update the product label, likely to add or modify an indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ZORYVE (ROFLUMILAST)

Snippet

SUPPL AP for ZORYVE (ROFLUMILAST)